NCT06541639

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection As a Single and Combination with Tislelizumab in Subjects with Advanced or Recurrent Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment. The main questions to answer are: Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.

Conditions

• Advanced or Recurrent Solid Tumors

Interventions

Type	Name	Description
BIOLOGICAL	EVM16	cancer vaccine
DRUG	Tislelizumab	Anti-PD1 antibody

Timeline

• Start date: 2025-03-04
• Primary completion: 2028-03-31
• Completion: 2028-06-30
• First posted: 2024-08-07
• Last updated: 2025-03-18

Locations

2 sites across 1 country: China